Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s13311-014-0293-y http://scihub22266oqcxt.onion/10.1007/s13311-014-0293-y C4391383!4391383 !24990202     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24990202 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Neurotherapeutics 2014 ; 11 (4 ): 786-95 Nephropedia Template TP {{tp|p=24990202 |t=2014. Spinal muscular atrophy: journeying from bench to bedside |pdf=|usr=}}{{24990202 }} gab.com Text Spinal muscular atrophy: journeying from bench to bedside JO: Neurotherapeutics http://www.kidney.de/pget.php?&tw=1&pmid=24990202 #FOAvip Spinal muscular atrophy (SMA) is a frequently fatal neuromuscular disorder and the most common inherited cause of infant mortality. SMA results from reduced levels of the survival of motor neuron (SMN) protein. Although the disease was first described more than a century ago, a precise understanding of its genetics was not obtained until the SMA genes were cloned in 1995. This was followed in rapid succession by experiments that assigned a role to the SMN protein in the proper splicing of genes, novel animal models of the disease, and the eventual use of the models in the pre clinical development of rational therapies for SMA. These successes have led the scientific and clinical communities to the cusp of what are expected to be the first truly promising treatments for the human disorder. Yet, important questions remain, not the least of which is how SMN paucity triggers a predominantly neuromuscular phenotype. Here we review how our understanding of the disease has evolved since the SMA genes were identified. We begin with a brief description of the genetics of SMA and the proposed roles of the SMN protein. We follow with an examination of how the genetics of the disease was exploited to develop genetically faithful animal models, and highlight the insights gained from their analysis. We end with a discussion of ongoing debates, future challenges, and the most promising treatments to have emerged from our current knowledge of the disease. Twit Text FOAVip Spinal muscular atrophy: journeying from bench to bedside ????Neurotherapeutics http://www.kidney.de/pget.php?&tw=1&pmid=24990202 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24990202 #FOAvip English Wikipedia <ref>{{Cite pmid|24990202 }}</ref> Spinal muscular atrophy: journeying from bench to bedside #MMPMID24990202 Awano T ; Kim JK ; Monani UR Neurotherapeutics 2014[Oct]; 11 (4 ): 786-95 PMID24990202 show ga Spinal muscular atrophy (SMA) is a frequently fatal neuromuscular disorder and the most common inherited cause of infant mortality. SMA results from reduced levels of the survival of motor neuron (SMN) protein. Although the disease was first described more than a century ago, a precise understanding of its genetics was not obtained until the SMA genes were cloned in 1995. This was followed in rapid succession by experiments that assigned a role to the SMN protein in the proper splicing of genes, novel animal models of the disease, and the eventual use of the models in the pre clinical development of rational therapies for SMA. These successes have led the scientific and clinical communities to the cusp of what are expected to be the first truly promising treatments for the human disorder. Yet, important questions remain, not the least of which is how SMN paucity triggers a predominantly neuromuscular phenotype. Here we review how our understanding of the disease has evolved since the SMA genes were identified. We begin with a brief description of the genetics of SMA and the proposed roles of the SMN protein. We follow with an examination of how the genetics of the disease was exploited to develop genetically faithful animal models, and highlight the insights gained from their analysis. We end with a discussion of ongoing debates, future challenges, and the most promising treatments to have emerged from our current knowledge of the disease. |Animals [MESH] |Cell Survival [MESH] |Disease Models, Animal [MESH] |Humans [MESH] |Mice [MESH] |Motor Neurons/metabolism/pathology [MESH] |Muscular Atrophy, Spinal/*genetics/therapy [MESH] |Survival of Motor Neuron 1 Protein/genetics [MESH] |Survival of Motor Neuron 2 Protein/genetics [MESH]Spinal muscular atrophy: journeying from bench to bedside (epmc).pdf DeepDyve Pubget Overpricing